The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.
PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE OR NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on that assumption, some 20 institutions representing different sectors of the health system launched the Personalized Medicine Coalition in 2004 to improve upon medical paradigms that base treatment decisions exclusively on population averages.

The Coalition advocates for changes that will increase investment in personalized medicine and facilitate its adoption so that both patients and the health system will benefit from improved clinical care and increased overall value.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient. By combining the data from those tests with an individual’s medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans.
AN EDUCATIONAL AND ADVOCACY ORGANIZATION, PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to encourage the advancement of personalized medicine. PMC’s priorities include:

• Developing and promoting regulatory policies that facilitate the efficient approval of personalized medicine products;

• Generating evidence and championing policy reforms to support an improved reimbursement environment for personalized medicine products and services; and

• Influencing provider practices to accelerate the pace at which personalized medicine is integrated in the clinic.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

— Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School
PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

BENEFITS OF MEMBERSHIP

PMC members:

• Shape the Coalition’s strategic agenda in education and advocacy;

• Stay up-to-date on the latest developments in personalized medicine via PMC’s member-only landscape analyses, reports and releases; and

• Publish thought leadership pieces in PMC’s blog, Education & Advocacy, and its bi-annual progress report, Personalized Medicine in Brief.

Other benefits include:

CONTACT
2,000+
leaders in personalized medicine via PMC’s member database

INTERACT WITH
200+
thought leaders from Congress, FDA, CMS and the private sector at member meetings and events

SAVE
40%
on registration for the Annual Personalized Medicine Conference
PMC MEMBERSHIP

A 501(c)3 organization, PMC is an independent, non-partisan educational and advocacy organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES
AlphaGenomix Laboratories
Empire Genomics
Laboratory Corporation of America (LabCorp)
Metabon, Inc.
Natera
Quest Diagnostics
Taliaz Health

DIAGNOSTIC COMPANIES
Agendia NV
Alacris Theranostics GmbH
Almac Diagnostics
Asuragen, Inc.
Caprion Proteomics
CareDx, Inc.
Caris Life Sciences
Celcuity, LLC
Cofactor Genomics
Diaceutics
Foundation Medicine, Inc.
GeneCentric Therapeutics
Genomic Health, Inc.
Guardant Health
Inivation
Invivoscribe Technologies, Inc.
Luminex Corporation
MolecularMD
NanoString Technologies
OmniSeq
QIAGEN, Inc.
Roche Diagnostics Corporation
Siemens Healthcare Diagnostics, Inc.
SomaLogic, Inc.
Veracyte

EMERGING BIOTECH/PHARMACEUTICAL COMPANIES
Aevi Genomic Medicine
AveXis
Freenome
Loxo Oncology
Neon Therapeutics
Regeneron
Relay Therapeutics
Syros Pharmaceuticals
Tango Therapeutics
Unum Therapeutics
WuXiNextCODE

HEALTH INSURANCE COMPANIES
Blue Cross Blue Shield Association
Harvard Pilgrim Health Care

INDUSTRY/TRADE ASSOCIATIONS
American Clinical Laboratory Association
BIO (Biotechnology Innovation Organization)
Biocom
PhRMA

IT/INFORMATICS COMPANIES
2bPrecise
Change Healthcare
Concert Genetics
Cota Healthcare
DNAnexus
Edico Genome
Flatiron Health
GNS Healthcare
M2Gen
Medidata
Oracle Health Sciences
PierianDx
Seven Bridges
Syapse
XIFIN, Inc.

LARGE BIOTECH/PHARMACEUTICAL COMPANIES
Amgen, Inc.
Astellas Pharma Global Development
AstraZeneca Pharmaceuticals
Boehringer-Ingelheim
Bristol-Myers Squibb
Celgene
Eli Lilly and Company
EMD Serono
Endo Health Solutions

Genentech, Inc.
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Takeda Pharmaceuticals, Inc.

NUTRITION, HEALTH & WELLNESS COMPANIES
International Vitamin Corporation

PATIENT ADVOCACY GROUPS
Accelerated Cure Project for Multiple Sclerosis
Alliance for Aging Research
Alzheimer’s Foundation of America
Asian and Pacific Islander American Health Forum
Bonnie J. Addario Lung Cancer Foundation
Bulgarian Association for Personalized Medicine
Emily’s Entourage
Fight Colorectal Cancer
Food Allergy Research and Education
Friends of Cancer Research
Global Liver Institute
HealthyWomen
International Cancer Advocacy Network (“ICAN”)
LUNGevity Foundation
Multiple Myeloma Research Foundation
National Alliance Against Disparities in Patient Health
National Alliance for Hispanic Health
National Blood Clot Alliance
National Health Council
National Patient Advocate Foundation
OpenCures
Susan Gurney Thrivors

PMC MEMBERSHIP

A 501(c)3 organization, PMC is an independent, non-partisan educational and advocacy organization with members that are committed to science-driven, evidence-based health care.
PERSONALIZED MEDICINE SERVICE PROVIDERS

23andMe
Genome Medical
Intervention Insights
KEW Group
Michael J. Bauer, M.D., & Associates, Inc.
MolecularHealth
N-of-One, Inc.
Panaceutics
Sema4
Tempus

RESEARCH, EDUCATION & CLINICAL CARE INSTITUTIONS

American Association for Cancer Research (AACR)
American Medical Association (AMA)
Association for Molecular Pathology (AMP)
Baylor Health Care System Precision Medicine Institute
Brigham and Women’s Hospital, Genomes2People Research Program
Brown University
Business Finland
Cancer Treatment Centers of America
Center for Medical Technology Policy
The Christ Hospital
College of American Pathologists
Colorado Center for Personalized Medicine
Coriell Institute for Medical Research
CREATE Health
Translational Cancer Centre, Lund University
Duke Center for Research on Personalized Health Care
Essentia Institute of Rural Health
Geisinger
Genome British Columbia
Genome Canada
Georgetown Lombardi Comprehensive Cancer Center
Harvard Business School
Helmholtz Zentrum München
Hospital Albert Einstein
Inova Health System
Instituto de Salud Carlos III
Intermountain Healthcare
The Jackson Laboratory
Johns Hopkins Individualized Health
King Faisal Specialist Hospital and Research Centre
Manchester University School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson – Institute for Personalized Cancer Therapy
Mission Health, Fullerton Genetics Center
Moffitt Cancer Center
National Pharmaceutical Council
Nicklaus Children’s Hospital Research Institute
North Carolina Biotechnology Center
NorthShore University HealthSystem
Ontario Genomics Institute
Partners HealthCare Personalized Medicine
Poliambulatorio Euganea Medica
Precision Health Initiative at Cedars-Sinai
Precision Medicine Alliance, LLC
Qatar Biobank
Quebec Network for Personalized Health Care
Rutgers Cancer Institute of New Jersey
Sanford Imagenetics, Sanford Health
Stanford University School of Medicine
Swedish Cancer Institute
Sylvester Comprehensive Cancer Center – University of Miami
UC Davis Mouse Biology Program
University of Alabama, Birmingham
University of Arizona Health Sciences
University of California, San Diego (UCSD)
University of California, San Francisco (UCSF)
University of Florida
University of Maryland School of Pharmacy
University of Pennsylvania Health System
University of Pittsburgh Medical Center (UPMC)
University of Rochester
University of South Florida Morsani College of Medicine
Vanderbilt University Medical Center
Wake Forest Baptist Medical Center
West Cancer Center

RESEARCH TOOL COMPANIES

Illumina, Inc.
Thermo Fisher Scientific

STRATEGIC PARTNERS

ADVI
Arnold & Porter Kaye Scholer, LLP
Artisan Healthcare Consulting
Bioscience Valuation BSV GmbH
Bruce Quinn Associates
Cambridge Healthtech Institute
Center for Individual Opportunity
Ceres Health Research
Clarity Research & Consulting
ConText
ConvergeHEALTH by Deloitte
CRD Associates, LLC
Credit Suisse
Defined Health
EdgeTech Law, LLP
EY Parthenon
Foley & Lardner, LLP
Foley Hoag, LLP
Genome magazine
GlobalData Plc
Goldbug Strategies, LLC
DUES STRUCTURE

Large Public Corporation $29,000
Small Public Corporation $14,500
Trade Association (based on revenues)
Private Corporation >50 FTEs $5,775
Professional Society $5,775
Private Corporation <50 FTEs $3,500
Strategic Partner $2,900
Research, Education & Clinical Care Institutions $2,900
Sole Proprietor $1,150
Patient Advocacy Group $500

Visit pmc.portal.membersuite.com to join the Coalition.

For more information, contact Kayla Smith, Director, Membership & Development, at ksmith@personalizedmedicinecoalition.org or 202-589-0070.
STAFF

Edward Abrahams, Ph.D.
President

Cynthia A. Bens
Senior Vice President,
Public Policy

Daryl Pritchard, Ph.D.
Senior Vice President,
Science Policy

Faswilla Sampson, M.S.
Vice President, Operations

Christopher J. Wells, M.P.A.
Vice President, Public Affairs

Kayla Smith
Director, Membership &
Development

David L. Davenport
Manager, Public Policy &
Secretary to the Board

BOARD OF DIRECTORS

Stephen L. Eck, M.D., Ph.D.
Board Chair
Immatics Biotechnologies

Jay G. Wohlgemuth, M.D.
Board Vice Chair
Quest Diagnostics

Peter Maag, Ph.D.
Board Treasurer
CareDx

Amy P. Abernethy, M.D., Ph.D.
Flatiron Health

Bonnie J. Addario
Bonne J. Addario Lung Cancer Foundation

Steven D. Averbuch, M.D.
Bristol-Myers Squibb Company

Paul R. Billings, M.D., Ph.D.
Natera

Randy Burkholder
PhRMA

William S. Dalton, Ph.D., M.D.
M2Gen

Tim Garnett, F.R.C.O.G.,
M.F.F.P., F.F.P.M.
Eli Lilly and Company

Brad Gray
NanoString Technologies

Kris Joshi, Ph.D.
Change Healthcare

Anne-Marie Martin, Ph.D.
Novartis

Susan McClure
Genome magazine

Howard L. McLeod, Pharm.D.
Moffitt Cancer Center

J. Brian Munroe
Bausch Health Companies

Lincoln Nadauld, M.D., Ph.D.
Intermountain Healthcare

Michael Pellini, M.D.
Section 32

Kimberly J. Popovits
Genomic Health

Hakan Sakul, Ph.D.
Pfizer, Inc.

Michael S. Sherman, M.D.,
M.B.A., M.S.
Harvard Pilgrim Health Care

Sean Tunis, M.D.
Center for Medical Technology Policy

Michael J. Vasconcelles, M.D.
Unum Therapeutics

Werner Verbiest
Janssen Diagnostics